Form 4: Monopar Therapeutics CFO Karthik Radhakrishnan Reports Acquisition of Common Stock
SEC Form 4 Filing
Karthik Radhakrishnan, CFO of Monopar Therapeutics, reports the acquisition of 1,550 shares of common stock at a price of $16.25 per share on October 28, 2024.
Summary
- On October 28, 2024, Karthik Radhakrishnan, the Chief Financial Officer of Monopar Therapeutics, acquired 1,550 shares of common stock.
- The shares were purchased at a price of $16.25 per share.
- This transaction was reported on a Form 4 filing with the Securities and Exchange Commission.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing. The CFO's purchase could be seen as slightly positive, but the filing itself is simply a reporting requirement.
Positives
- The CFO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and are required by the SEC when company insiders, such as officers and directors, trade their company's stock. These filings provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 10/28/2024 | Date of transaction: Karthik Radhakrishnan acquired 1,550 shares of common stock at $16.25 per share. |
| 10/30/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.